Videos

Although immunotherapy progress in prostate cancer has been slow, emerging strategies like bispecific T-cell engagers (BiTEs) show promise in overcoming historical resistance.

Real-time ctDNA MRD testing guides early chemo de-escalation in diffuse large B-cell lymphoma, aiming to cut toxicity without losing cure rates.

Althopugh current prostate cancer biomarkers have improved the detection of clinically significant disease (Gleason Grade Group 2+), they fail to distinguish between high-grade cancer and genuinely lethal cancer, potentially leading to overtreatment and underscoring the need for next-generation tools that identify patients at true mortality risk.

In an interview, Vincent Ma, MD, explores the clinical utility of circulating tumor DNA dynamics to assess early outcomes in patients with melanoma.

Natalie Berger, MD, weighed the biggest hurdles she witnesses in HPV vaccination and screening adherences.

ctDNA MRD monitoring offers new clues for stopping chemo safely in metastatic gastroesophageal cancer, linking molecular response to outcomes.

David R. Wise, MD, PhD, discusses the use of gotistobart, a next-generation CTLA-4 targeting antibody, in prostate cancer.

ctDNA MRD monitoring may augment scans and tumor markers, enabling earlier detection of gastroesophageal cancer recurrence, especially hard-to-image peritoneal relapse.

Vincent Ma, MD, discusses a study evaluating circulating tumor DNA early in treatment of metastatic melanoma using immune checkpoint inhibitors.

PODIUM-03 shows retifanlimab plus carboplatin/paclitaxel boosts response and survival, reshaping first-line care for advanced anal cancer.

Tumor board insights reveal how ctDNA-guided ESR1 testing and SERENA-6 strategies may reshape HR+ metastatic breast cancer and local therapy choices.

See how breast cancer endocrine and targeted drugs inform endometrial and ovarian care—tamoxifen, CDK4/6 combos, and T-DXd.

Effectively assessing anemia in myelofibrosis goes beyond hemoglobin levels, and should focus on symptoms, daily function, and quality of life to guide treatment.

Paul G. Richardson, MD, discusses the SUCCESSOR-2 trial of mezigdomide, carfilzomib, and dexamethasone in multiple myeloma.

Early-phase clinical trials involving PIM-1 kinase inhibitors look promising.

Researchers launch a public immune atlas of pancreatic cancer therapy responses, allowing the public to rapidly link pancreatic cancer immunotherapy trials to immune shifts and outcomes.

Cabozantinib offers significant benefits for patients progressing on octreotide LAR, especially those with prior treatments and specific conditions.

CD25 rewires oncogene signaling in AML and ALL, revealing druggable complexes and a bold strategy: push pathways into toxic overdrive.

Dr Saad explores the emerging role of radiopharmaceuticals in prostate cancer.

Medicaid expansion has boosted breast cancer survival rates, especially for Hispanic women, highlighting ACA policy impact.

Experts weigh perioperative immunotherapy delays, rapid molecular testing, ctDNA MRD and emerging ADCs shaping early-stage lung cancer care.

Dr Ghatalia discusses RETAIN-2, highlighting ctDNA analysis drawn from RETAIN-1 and RETAIN-2.

Sagar Lonial, MD, discusses the significance of the MRD end point for the ongoing priority review of iberdomide in multiple myeloma.

Using the best medication available in the frontline setting of RCC leads to optimal results.

Efficacy and safety results from the phase 1 PAnTHA study presented at 2026 ASCO GU.

Study reveals CD25 tunes tyrosine kinase signaling into a Goldilocks sweet spot, helping AML and ALL cells resist treatment and grow.

Understanding the safety profile of belzutifan (Welireg) will expand its use role in RCC.

TTLC 2026 spotlights next-gen lung cancer therapies, co-mutation strategies, and ctDNA monitoring—insights beyond CME for what’s coming next.

In this episode, Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, discusses the future of BPCDN treatment and how a collaborative care model should play a role in this rare disease.

In this episode, Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, offers an overview of pivekimab sunirine and CD123-directed antibody-drug conjugates (ADCs) in the BPDCN pipeline.